Company news
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) news
Every Arcturus Therapeutics Holdings Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
July 28, 2026
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
July 20, 2026
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
July 2, 2026
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 26, 2026
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
May 7, 2026
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
April 27, 2026
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
March 3, 2026
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
February 17, 2026
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Arcturus Therapeutics to Attend Upcoming Investor Conference
November 24, 2025
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
November 10, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
November 4, 2025
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
October 28, 2025
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
October 22, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
August 11, 2025
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
July 24, 2025
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
June 30, 2025
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC)...
June 23, 2025
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
May 12, 2025
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
April 22, 2025
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A V...
April 10, 2025
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
March 6, 2025
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
March 5, 2025
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
February 24, 2025
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 14, 2025
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 14, 2025
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
February 4, 2025
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Again...
January 31, 2025
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
January 30, 2025
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
January 10, 2025
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Tr...
January 6, 2025
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
November 18, 2024
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
November 11, 2024
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
November 7, 2024
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
October 31, 2024
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
September 30, 2024
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for P...
September 13, 2024
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for P...
September 13, 2024
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an...
September 3, 2024
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 27, 2024
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 5, 2024
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
August 1, 2024
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 18, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
July 1, 2024
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 20, 2024
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
June 7, 2024
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 28, 2024
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
May 20, 2024
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024